LOADING
Tag: Incytes
Leo Pharma prepares to come for the topical JAK market as Incyte’s Opzelura cream launch cools off
May 4, 2024
Watch out, Incyte. Leo Pharma and its JAK inhibitor cream delgocitinib are coming to disrupt the topical atopic dermatitis market, currently inhibited by Incyte’s approved Opzelura. With several positive studies in hand, including a recent phase 3 trial pitting the candidate against the current standard-of-care, Leo says its delgocitinib has growth driver potential. Now, the drugmaker […]
chat_bubble0 Comment
visibility193 Views
FDA approves new vitiligo treatment, bolstering Incyte’s dermatology business
July 19, 2022
The Food and Drug Administration has approved a first-of-its-kind treatment for vitiligo, a condition that causes patches of discoloration on the skin and, currently, has few other therapeutic options. The treatment, known as ruxolitinib, is now the only one approved in the U.S. to repigment skin in people with the most common, “nonsegmental” form of […]
chat_bubble0 Comment
visibility472 Views